Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8656644 | 0.84 | KEAP1 (0.78) | KEAP1ESR1ESR2MAPTMEN1 | |
| SCHEMBL3814505 | 0.83 | MEN1 (0.50) | KEAP1MAPTGAAMEN1KMT2A | |
| SCHEMBL3357458 | 0.83 | CALM1 (0.55) | MEN1KMT2AIDO1PNMT | |
| SCHEMBL4423210 | 0.82 | SIGMAR1 (0.53) | MEN1KMT2AIDO1PNMT | |
| SCHEMBL21632758 | 0.82 | ESR1 (0.56) | KEAP1ESR1ESR2MAPTGAA | |
| SCHEMBL2089904 | 0.79 | KDM4E (0.53) | MAPTTP53MEN1KMT2AIDO1 | |
| SCHEMBL3438629 | 0.79 | TAAR1 (0.47) | TP53IDO1PNMTCXCR4SLC5A1 | |
| SCHEMBL48241 | 0.79 | TAAR1 (0.47) | TP53MEN1KMT2AIDO1PNMT | |
| SCHEMBL21186239 | 0.79 | ALDH1A1 (0.52) | IDO1PNMT | |
| SCHEMBL8752818 | 0.79 | SMN1; SMN2 (0.47) | IDO1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489226-B1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-109867648-A | A kind of synthetic method of Yi Palie only in relation to substance IMPD | 浙江医药股份有限公司新昌制药厂 | 2019-06-11 | — | — | CN | disclosed |
| EP-3489226-A1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | Lexicon Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-2925735-B1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| CN-102854744-B | The manufacture method of photosensitive polymer combination and hardening thing and photoresist | 东洋油墨SC控股株式会社 | 2016-06-29 | — | — | CN | disclosed |
| CN-102854744-A | Photosensitive resin composition, cured product thereof, and method for producing photosensitive resin | TOYO INK SC HOLDINGS CO LTD | 2013-01-02 | — | — | CN | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-0215312-A1 | Method for producing of polyarylene sulfides | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | KEAP1 3948/4885ESR1 4066/4885ESR2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.